Abstract Title: currently loading...

information currently loading...

close
Loading ... please wait
timer Loading ... please wait

Free Paper Session 20: AMD IV

10:30 - 12:00 | 08 September | Room: Room 241

Back to Previous

10:30CANTREAT study 24-month results: the ability to extend treatment and associated visual outcomes in the treat and extend group
P. Kertes Canada
10:42Long-term follow-up of quiescent choroidal neovascularization associated with age related macular degeneration or pachychoroid
R. Forte France
10:48Determinants of quality of life in geographic atrophy secondary to age-related macular degeneration
S. Künzel Germany
10:54Assessment of ellipsoid zone reflectivity by optical coherence tomography in eyes at high risk for development of late-stage AMD over time
S. Thiele Germany
11:06Evaluation of the role of autologous bone marrow derived mononuclear cells in advanced dry AMD
S. Simakurthy India
11:12Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year interim results of rainbow
S. Baillif France
11:1810-year mortality and clinical outcomes in patients with neovascular age-related macular degeneration treated with intravitreal anti-VEGF (vascular endothelial growth factor) injections
S. Young United Kingdom
11:24To what extent do patients with exudative age-related macular degeneration, treated out-with current UK guidelines, gain improvement in visual acuity (VA)?
T. Davies United Kingdom
11:307-year outcomes of anti-VEGF treatment in exsudative age-related macular degeneration
J. Bernardes Portugal
11:36The efficacy and safety of brolucizumab compared with aflibercept in polypoidal choroidal vasculopathy: 24-month results from the HAWK study
Y. Ogura Japan
11:42Association between changes in anatomical, functional outcomes and physicians’ decisions to treat patients with licensed anti-VEGFs for neovascular age-related macular degeneration (nAMD) in the UK
U. Chakravarthy United Kingdom
11:48Factor H-related protein 4 drives complement activation in age-related macular degeneration
V. Cipriani United Kingdom
Back to Previous

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved